ESTIMATED COSTS FOR ALL-CAUSE GRADE 3/4 ADVERSE EVENTS AMONG FIRST-LINE TYROSINE KINASE INHIBITOR PLUS IMMUNO-ONCOLOGY-BASED COMBINATION THERAPIES FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA FROM THE UNITED STATES PERSPECTIVE

被引：0
|
作者：
Wallace, J. F. [1 ]
Adair, N. [2 ]
Perez, J. R. [1 ]
Hall, T. [1 ]
Bilen, M. A. [3 ]
Sussman, M. [2 ]
机构：
[1] Exelixis Inc, Alameda, CA USA
[2] Panalgo LLC, Boston, MA USA
[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE140
引用
收藏
页码：S361 / S361
页数：1
相关论文
共 5 条
  • [1] Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma
    McGregor, Bradley
    Geynisman, Daniel M.
    Burotto, Mauricio
    Porta, Camillo
    Suarez, Cristina
    Bourlon, Maria T.
    Del Tejo, Viviana
    Du, Ella X.
    Yang, Xiaoran
    Sendhil, Selvam R.
    Betts, Keith A.
    Huo, Stephen
    ONCOLOGIST, 2023, 28 (01): : 72 - 79
  • [2] The Role of Nurses in the Management of Adverse Events in Patients Receiving First-Line Axitinib Plus Immuno-Oncology Agents for Advanced Renal Cell Carcinoma
    Parreira, Sara
    Burns, Kathleen
    Moldawer, Nancy
    Zomordian, Nazy
    Bandali, Nesan
    Virdee, Kiran
    Walsh, Meghara
    Kelly, Daniel
    Rao, Dharanija
    Teresi, Rosemary
    Wood, Laura S.
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
  • [3] Trial-based costs of all-cause adverse events in first-line therapy for advanced non-small cell lung cancer: Findings from CheckMate-227
    Lubinga, S. J.
    King, S. B.
    Betts, K. A.
    Rao, S.
    Castriota, F.
    Mahin, M.
    Orvis, E.
    Marathe, S.
    Ma, J.
    Stenehjem, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S827 - S828
  • [4] Trial-based costs of all-cause adverse events in first-line therapy for advanced non-small cell lung cancer: Findings from CheckMate-9LA
    Stenehjem, D.
    Lubinga, S. J.
    King, S. B.
    Betts, K. A.
    Rao, S.
    Castriota, F.
    Mahin, M.
    Orvis, E.
    Marathe, S.
    Ma, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S850 - S851
  • [5] TREATMENT COSTS OF GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN
    de Castro Carpeno, J.
    Banz, K.
    Castro, A. J.
    VALUE IN HEALTH, 2009, 12 (07) : A264 - A264
1